ELCC 2017: Sponsor & Exhibitor Profiles
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis.
- Booth number: 3
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit the company website.
- Booth number: 2
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
- Booth number: 12
MSD Merck Sharp & Dohme AG
MSD is a global healthcare leader working to help the world be well.
- Booth number: 11
Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives.
- Booth number: 10
Boehringer Ingelheim is committed to delivering novel anti-cancer agents that address unmet needs across a broad range of solid and haematological malignancies. For lung cancer, Boehringer Ingelheim has two agents approved* in many countries for specific NSCLC sub-types. The oncology portfolio is supported by a strong early pipeline and an active partnering strategy to further strengthen our presence in this key therapeutic area.
* Nintedanib in NSCLC is not approved in Switzerland.
- Booth number: 14
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab, as a monotherapy, as well as combination regimens, and is striving to find new ways to treat cancer.
- Booth number: 15
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. Its mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. For more information, please visit the company website.
- Booth number: 16b
F. Hoffmann-La Roche Ltd
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Lung cancer is a major area of focus and investment for Roche, with the objective to develop new approaches, medicines and tests that can help people with this deadly disease. With the combined strength in pharmaceuticals and diagnostics, Roche is dedicated to further drive personalised healthcare. The Roche Group, headquartered in Basel, is active in over 100 countries and employs more than 94,000 people worldwide.
- Booth number: 30
Novartis Oncology is a global leader in improving outcomes for patients. We seek to transform cancer care through distinctive scientific and clinical strategies focused on developing targeted, immuno-oncology and combination therapies to create more effective options for patients. For more information, please visit the company website.
- Booth number: 17
Otsuka Pharmaceutical Europe Ltd
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' The Otsuka Group is comprised of 178 companies and employs approximately 47,000 people globally with products available in over 80 countries worldwide. Otsuka’s employees focus their energy into ensuring that patients have access to Otsuka’s innovative products and medical devices in our key therapy areas of mental health, endocrinology, nephrology, gastroenterology and oncology.
Headquartered in Basel, Switzerland, one of the two divisions of the Roche Group, 29,300 employees worldwide in 130 countries. Number 1 in the in vitro diagnostics market. Roche has established itself as leader in personalised healthcare (PHC). The development of diagnostic assays are guiding clinical strategy internally within Roche and externally. Companion Diagnostics can help to make PHC a reality. For more information, please visit the company website.
- Booth number: 29
Biocartis aims to provide direct access to personalized medicine for patients worldwide by developing fully integrated, broadly applicable molecular diagnostics. Biocartis’ MDx Idylla™ platform is a fully automated sample-to-result, real-time Polymerase Chain Reaction system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting.
- Booth number: 13A
Takeda Oncology is dedicated to developing and delivering novel medicines to cancer patients worldwide through our science, innovation, and passion. With our recent acquisition of ARIAD Pharmaceuticals, a leader in targeted oncology therapies, we are strengthening and diversifying our therapeutic areas. Our legacy includes therapies for hematologic cancers and solid tumors, including lung cancer. We aspire to cure cancer.
- Booth number: 16A
Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based provider of state-of-the-art diagnostic products and services in the area of human oncology personalised healthcare. We have a rich portfolio of tests that focuses on detecting mutations and measuring gene expression in various sample types including FFPE cancer tissue, body fluids, and whole blood.
- Booth number: 13B
Beacon Oncology Limited
BEACON Oncology Limited (BOL) is the number one oncology company in Bangladesh. Beacon Oncology is the sister concern of Beacon Group.
BEACON manufactures about 76 oncology products including latest chemotherapy drugs, targeted therapies hormonal drugs & monoclonal antibody. BEACON has dedicated oncology facilities which conforms to US FDA,UK MHRA, TGA Australia and WHO GMP. BEACON exports its anti-cancer drugs to many countries of Asia and Africa.
- Booth number: 28
Premium Educational Grant Sponsor
PharmaMar is a global commercial stage biopharmaceutical company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with novel mechanisms of action with antitumor activity. We are a fully integrated company from discovery to commercialization that seeks innovative products to provide healthcare professionals and patients with new tools to treat cancer. With subsidiaries in Europe and the United States, and strong corporate partners such as Janssen, Chugai and Taiho, PharmaMar has an important late stage pipeline of drug candidates as well as a robust R&D oncology program.
Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.
- Booth number: 18